2022 World Conference on Lung Cancer (ePosters)-EP08.02-098. Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC

Pdf Summary

The EVOKE-02 study is an exploratory Phase 2 study designed to determine the optimal combination of sacituzumab govitecan (SG), pembrolizumab, and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients without actionable genomic alterations. NSCLC is the leading cause of cancer-related deaths in the US, and current standard treatments for metastatic NSCLC include immune checkpoint inhibitor therapy, platinum-based chemotherapy, or a combination of the two. However, many patients either do not respond to these treatments or develop progressive disease.<br /><br />SG is an antibody-drug conjugate that has shown promising results in previous studies for the treatment of advanced epithelial cancers. In the phase 1/2 IMMU-132-01 study, SG demonstrated an objective response rate of 16.7% and a median overall survival of 9.5 months in patients with metastatic NSCLC.<br /><br />The EVOKE-02 study aims to improve outcomes by combining SG with pembrolizumab and platinum chemotherapy in the first-line setting. The study is currently ongoing and has enrolled patients across multiple sites in North America, Europe, and Asia.<br /><br />The study design includes randomized assignment to different treatment cohorts, with overlapping eligibility criteria. The objective is to determine the recommended phase 2 dose of SG and assess the preliminary efficacy and safety of the combinations.<br /><br />This study is sponsored by Gilead Sciences, Inc., and the authors acknowledge the patients and caregivers for their participation, as well as the clinical trial investigators and team members.<br /><br />The key eligibility criteria for participation in the EVOKE-02 study include patients with stage IV NSCLC without known genomic alterations in actionable driver oncogenes. Patients should not have received prior systemic treatment for metastatic NSCLC and should have an Eastern Cooperative Oncology Group performance score of 0 or 1.<br /><br />Overall, the EVOKE-02 study aims to explore a potential treatment option for patients with advanced NSCLC, utilizing a combination of SG, pembrolizumab, and chemotherapy in the first-line setting.

Asset Subtitle

Martin Reck

Meta Tag

Speaker Martin Reck

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EVOKE-02 study

sacituzumab govitecan

pembrolizumab

chemotherapy

metastatic non-small cell lung cancer

NSCLC

immune checkpoint inhibitor therapy

platinum-based chemotherapy

antibody-drug conjugate

metastatic NSCLC